CPGR Blog

Highly concentrated scientific productivity and its impact on Africa

A recent paper in PLoS one [1] suggests that less than 1% of the globally active scientific community accounts for about 42% of all research output (measure = scientific publications; observation period = 1996-2011). If only high-impact papers are considered, a core group of scientists accounts for 87% of all publications. Through mining of appropriate data, [...]

Continue Reading 0

A snapshot of global trends, challenges and drivers of success in Research & Development (R&D)

A recent publication by Battelle provides a global overview and forecast of R&D spending as well as related challenges and drivers of success. What follows is a summary of key messages (text and figures), extracted from the Battelle report (2014 Global R&D Funding Forecast): The world share of R&D spend doesn’t change significantly within a 3-year observation [...]

Continue Reading 0
Platform launch large

CPGR NGS platform launch

In May 2014, the CPGR will boost its Genomics offering with the addition of four high-end next-generation sequencing instruments. The organisation’s enhanced capacity will comprise of 1 MiSeq (Illumina), 2 Ion Torrent PGMs (Life Technologies) and 1 Ion Proton (Life Technologies). We will employ a blend of sequencing technologies to offer the best possible support [...]

Continue Reading 0

What indicators should we use to predict success of R&D in pharma & life science organisations?

A recent opinion piece in Nature Reviews Drug Discovery (NRDD) investigates indicators of R&D (research & development) productivity (as measured by project success rate or Return on Investment, ROI) in pharmaceutical organisations. The findings presented in the paper have relevance for life science organisations with R&D focus as a whole. As a basis for the study, the [...]

Continue Reading 0
Logo thumbnail

How industry dynamics force CROs to innovate and create opportunities for building biotech capacity in Africa

Overview While optimists have labelled the early 2000s as the dawn of the ‘Biomedical Century’ (1), a little more than 10 years into it many are bearish when thinking about the sector’s prospects. Among other factors, this viewpoint is guided by the declining R&D productivity in the pharmaceutical industry (as measured in number of approved [...]

Continue Reading 0

Considerations regarding a viable technology platform model

In many countries, developed and emerging, research infrastructure (RI) is considered either an entitlement by the academic elite or an expense by those holding the purse strings. In my mind, it is neither! Rather, it is an investment made in service of a particular purpose, and meant to yield returns for a variety of concerned [...]

Continue Reading 0

A compact for biomarker development in South Africa

Recently, the CPGR joined The Biomarkers Consortium. The ‘Biomarkers Consortium’, or ‘Consortium’, is a public-private scientific partnership between the Foundation for the National Institutes of Health (FNIH), the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Centres for Medicare & Medicaid Services (CMS), members of the pharmaceutical, biotechnology, diagnostics, and medical device [...]

Continue Reading 0

Is digital and online learning disrupting traditional (higher) education?

A series of articles appearing on the websites of the Economist (1) and Nature (2, 3) point to the radical shifts in (higher) education brought about by advancements made in digital and online learning. It’s good to see the inklings of disruptive innovation in the making, challenging the status quo of many an ivory tower. [...]

Continue Reading 0

Does a country’s ‘innovation readiness’ translate into economic impact?

A recent article on Nature’s Trade Secrets Blog1 looked at ways to measure a country’s attractiveness for biotech investment. Specifically, it explored a possible relationship between the 2013 Scientific American’s innovation scorecard data2 and the 2013 edition of a recently developed Venture Capital and Private Equity (VCPE) attractiveness index3. A replication of the regression analysis performed in [...]

Continue Reading 0

Careful selection of CROs in early-stage drug discovery & development may enhance pharmaceutical innovation

A July 2013 Nature Reviews Drug Discovery paper (1) highlights features of academia-industry collaborations in early-stage drug development. Specifically, the authors present a number of important points to consider when selecting a CRO (Contract Research Organisation) for progressing University-produced research outputs into the next stages of the pharmaceutical innovation chain. Although not discussed in detail, the paper [...]

Continue Reading 0